ACR 2026 RheumNow RA Topic Compilation c Save
Lifestyle Interventions and Biological Effects in RA
First theranostic approach to treat difficult-to-treat RA
Biologics after Cancer Is it Safe
RA-ILD and Lung Cancer
Disease Activity in RA-ILD Worse Survival, Unclear Lung Progression
Infliximab Biosimilar Switching
Anti-CCP Antibody Testing on the Spot
Transcription
This is an ACR twenty twenty six podcast coming to you from ACR in Orlando. Hope you enjoy it. Great rheumatologists go to great meetings like this. RoomNow live twenty twenty seven is happening January 3031 in Dallas, Texas. Join your colleagues from across the country and around the world for an interactive, engaging, and practice changing event.
Go to rheumnow.live to see the full program and register today. Hi, everyone. Jack Cush, ACR twenty twenty six Orlando, live in the room now booth where there's been a lot of action, a lot of significant teachers and, learners sharing their information with you at this meeting. I've been a bit overwhelmed, but what I... But...
About what I've seen. I want to talk to you about something I saw this morning. The lead presentation at the plenary session, twenty eight zero three is the abstract number. Hannah McClellan from the Duke University School of Medicine, the Molecular Physiology Institute, I think had a fabulous presentation on the impact of lifestyle interventions in older adults with rheumatoid arthritis looking specifically at immune signaling. So we can imagine that's gonna work, right, clinically and give some kind of benefit to people.
But are there immunologic correlates to what happens with lifestyle intervention? What we're talking about here is, especially as RA patients get older, sarcopenia is a problem at least twenty five percent. Patients get weaker, and getting weaker, they do less, they do less, they hurt more, they hurt more, they do less. It's a spiral down. Right?
I always try to get my older patients with RA to make their number one goal getting strong. If you get strong, things get better. And that's what they did in this trial. The trial was called sweat and chat. And what they did was...
It's a sixteen week trial of older RA patients. They're seropositive, and they are randomized to either sixteen weeks of two visits about diet, exercise, counseling, and then, and that's the chat cohort, the control cohort. The active intervention cohort is the sweat cohort, s w e t by the way, where they get regular ongoing aerobic resistance exercise training where they're aiming at a hundred and fifty minutes a week and that along with dietary interventions and then doing a readout on that at the end of the study period. The results were pretty dramatic. So they did get better with the intervention and the clinical improvement was shown significant clinical improvement in dash 28 CRP, in swollen joint count, and patient global assessments were all significant.
Sed rate and CRP, not significant. Interestingly, cytokines across the board, no change. But cellular subset analysis done by facts showed significant decreases in Treg cells, in CD four PD one cells, in CD four memory cells, and NK cells across the board for the people that had the active intervention, lifestyle intervention of diet and vigorous exercise. As I said, the plethora of metabolic and cytokine readouts showed no significance. And then they went on to show a lot of correlation with these biologic findings with clinical effects and you have to look at the abstract to really see what that all that meant.
In the end, they showed that very clearly that the lifestyle intervention led to, a modulation of lymphocyte profiling. Okay? And basically changed patients from... As far as their strength, their tone, their RA activity, changed them from, you know, sort of a failing older patient to someone whose biology was that of a younger patient. And the net result is that, you know, lymphocytes, disease activity, and muscle properties were greatly enhanced by the lifestyle intervention.
This was a pilot trial. Right? So there's only twenty people that that had the intervention. But I think it's strong data about what we should be doing and certainly a call for more information about lifestyle interventions and what the benefits are gonna be in rheumatoid arthritis. Tune in for more RheumNow.
Hello. I'm Jonathan Kaye from UMass Chan Medical School in Worcester, Massachusetts reporting for RheumNow at ACR Convergence twenty twenty six in Orlando, Florida. Today, I have Peter Mandel and Gregor Mitter from the University of Vienna, School of Medicine who've been presenting a very interesting poster about the use of fibroblast activation protein inhibitor coupled to lutetium, a radio labeled nucleotide or a nuclide to target the fibroblasts in rheumatoid arthritis synovium and treat active rheumatoid arthritis that's been resistant to other conventional therapies. So Peter, Gregor, tell us a little bit about what you found.
Yeah. So we had two patients, one with RA and one with PSA, who were difficult to treat with a long standing story of multiple drug failure. We tried to make this approach, which has been known to oncology, to inject intravenously fibroblast activation protein inhibitor coupled with lutetium. We saw quite good results in decrease of C. Diffeile, swollen joint count, tender joint count in both patients.
So this is very interesting. And Peter, you're targeting tissue resident fibroblasts. It's very difficult to target fibroblasts because unlike circulating t cells or b cells, these are in the synovium. How did you come up with this novel idea to take this approach?
So as Greg already mentioned, this approach is already used. This compound is already used in oncology where the idea is of course to target, bring the, the lutetium is a beta emitter, so it's a systemic radio ligand therapy. In our case, there the idea is that it would, because each tumor has a fibroblast environment or structure around it, that it would bring thereby the emitter within the vicinity of the tumor cells. In our case, this would be in a way analogous to radio synovial orthesis where we would inject it into a single joint, but in our case, we give this systemically. And we do see, we saw very, you know, in our diagnostic studies, we do see high uptake of of the the gallium label so that the diagnostic FAPI, in the synovial joints of patients, the two patients, Gregor mentioned, with with difficult to treat one with RA and the other one with PSA.
So this is a targeted approach, going back to the, probably twenty, thirty years ago using yttrium, injected into the joint in a nonspecific way of ablating the inflamed synovium. But here, you're using a targeted agent to target those fibroblasts that are probably pathogenic in the synovium.
Yes. It it... As analogy, this is not napalm bombing a forest, but a... If if if you may, a targeted intervention of a certain species of plants.
So this is fantastic. Where do you see this going? You've treated two patients. One with so called difficult to treat rheumatoid arthritis, another with multidrug experience psoriatic arthritis. What are your current plans for further development?
So obviously we want to take this forward and treat more patients. So what we've seen importantly is we saw both in a decrease in the standardized uptake values on the follow-up PET if we did that. We also did sino biopsies of these patients before and after the treatment and saw a reduction in the number of fat positive expressing fibroblasts. And we did see, particularly in the RA patient, a steady reduction of disease activity.
So this is wonderful. So this is now a new era of targeted therapies, but using radionuclide instead of antibodies or other protein derived drugs to treat difficult to treat rheumatoid arthritis and other forms of inflammatory arthritis. For more information about this and other topics, please go to roomnow.com. I'm Jonathan Kaye with Peter Mandel and Gregor Mitter, here at ACR Convergence twenty twenty six. See you again soon.
Thanks.
David
Lu here for RheumNow's coverage of ACI Convergence twenty twenty six, and I'm gonna hit some RA things today. Really interesting posters out there on the poster floor, answering the questions that we're... We come across in everyday practice. One of those that gets raised a bit and I think it started a long time ago when we didn't have certainty about things is about whether in a patient with RA who's had cancer, which does happen, is it okay to restart the biologic in the couple of years after, at any point after? What do we do about that?
And original guidance, if you go back, say fifteen years ago, was very conservative on this, that we should do it very cautiously, whether some people were withholding biologics for five years after. And it's very hard to get the data for these things as well for a number of reasons. Firstly, the outcome fundamentally is about new cancers coming back, new cancer coming back. And that takes time. There are a lot of factors that go into that that confound the situation.
It's hard to study these things ethically as well and so what inevitably happens is that we're reliant on observational data. You go back, I think two years ago now, just under two years... Well, just under two years ago, we saw some really excellent, data from Maria Suarez Almazar's group, at MD Anderson, looking at the situations where we gave biologics in that period of time, a couple of years after cancer diagnosis in lung cancer, some big cancers, colorectal cancer. We saw that actually the outcomes seemed pretty favorable. They were relatively small numbers.
It's a pretty big cancer centre, but it's still only one single centre. At this meeting, abstract two four zero nine was a big Spanish collaborative, with names you might have heard of, talking about this, they have a registry called the ARCA registry, the ARCA registry, where they've tried to put together a lot of these data, for different biologics. I should say that the MD Anderson, data was only TNF inhibitors and I guess there's questions about other, biologic, agents including abatacept and what that might mean for cancer recurrence versus something like methotrexate or a CSD mod which I guess we're more comfortable with possibly just from the basis of more experience. Seven twenty eight patients with rheumatoid arthritis, all of whom had previous cancer followed over the course of time. We don't have all the data on exactly when things were initiated and that's a fundamental limitation.
But what I will tell you is that they did not find any differences, significant differences between the biologics and the CS DMARDs. But if anything, things trended that, in fact, the biology DMARD patients did better in terms of cancer free survival, in terms of new instant cancers. So what does that mean? Well, I will tell you that naturally there's gonna be some channeling bias in that period of time over the course of decades. And, knowing that maybe those higher risk for recurrence or new cancer patients are going to have had some CSD MADs preferentially over having recommenced or started in biologics.
But all the signals do seem to suggest that if anything, there doesn't... There's not the same, point of concern there, and you have to ask yourself the concern that we've had with this is that at best overcautious and actually probably not based on things knowing that it's a very real cost in not giving rheumatoid arthritis patients the effective therapies they deserve and knowing as well that in a number of different other situations including with people receiving biologics for immune related adverse events for checkpoint inhibitors that we do use them in these situations and the world doesn't entirely fall in that situation either. So hopefully a bit of reassurance with that. Everything great on rheumatoid arthritis, you know where to go, roomnow.com.
Hello, everyone. I'm Richard Conway from Dublin, Ireland. I'm reporting from ACR twenty twenty six for RheumNow. I'm here to talk to you today about an abstract that was presented at Monday's abstract session. And this is an ILD abstract, but I think maybe some ILD people will not have encountered it as was presented in the epidemiology and public health abstract session and not the rheumatoid abstract session.
This is by Kim et al from Korea. And the proper title of this is Lung Cancer Risk in RA and RA A Competing Risk Analysis. I've called it RA ILD in lung cancer. I think that's, it does what it says on the team. That's what it's about.
This is a single center cohort, relatively large numbers of patients, however, six sixty four rheumatoid arthritis patients, two thirty of those had ILD, which is a lot. That is more than a third of their patients. So it seems ILD is quite common in Korea. So that was one of the things they were looking at. And the other thing was lung cancer.
Lung cancer, thankfully, slightly less common seen in thirteen patients in this cohort. Ten of those had ILD and three patients who didn't have ILD. When just looking at the basic demographics here, kind of as you'd expect, patients with ILD were more likely to be older. They're more likely to be men. They're more likely to be smokers.
So all kind of known risk factors for ILD and all also known risk factors for lung cancer. So one question with studies of this nature is always, is this just shared risk factors giving us these two conditions? But the authors, in fairness, have tried to control for that in, I would say, relatively complicated statistical methodology. So those rolling numbers, they give us an incident rate of lung cancer in patients with RA ILD of one point one three per one hundred patient years and in those without ILD, but who still have RA of zero point one two per one hundred patient years. They then looked at this in two main ways.
The first was inverse probability of treatment rating propensity score analysis methodology. That gave us an adjusted incident ratio of seven point one for lung cancer in patients who had RA LD compared to those with just RA. So that was quite high. There are relatively large confidence intervals on this being generated by relatively small numbers of patients who had lung cancer. So it went from one point four eight to thirty four point zero seven.
So it's hard to get an exact estimate, but certainly significantly more common in patients with ILD. They then went on and did another analysis, competing risk analysis, and that kind of confirmed the same findings. The hazard ratio here was 8.13. Again, confidence intervals are low, slightly less so going from 2.43 to 27.16. So that is giving us a relatively clear evidence here that these patients are more likely to get lung cancer and that we should be on lookout for it.
I guess there is always the possibility of bias around testing here. Patients with ILD will generally be under relatively closer follow-up. They'll be seen quite possibly by a respiratory physician as well as a rheumatologist. They may be getting serial CT scans, which of course will identify lung cancer at an earlier stage. So there's the possibility here that we're picking up more lung cancers either because we're seeing them earlier and they haven't yet been diagnosed in the RA population, or that we are seeing them because we're doing more testing and we're picking up lung cancers that would never have been a clinically significant problem.
I don't have a good feel for how true that is in lung cancer. It's obviously that happens a lot in things like prostate cancer, probably slightly less of a realistic explanation for lung cancer, which tends to be quite aggressive. So overall, I think this tells us we need to think about lung cancer in these patients. I'm not sure it would hugely change my clinical practice. I think obviously these patients were already on the lookout for their pulmonary outcomes and any change in their pulmonary status.
So I'm not sure it will hugely change what I do. Perhaps in that kind of relatively stable ILD population who may not be getting serial scans, I might start to think that maybe we should be doing them more frequently and delight my radiologist when I suggest they need to do more scans on these people as screening tests. So check out my Twitter at rechickpaconway for more of my content from ACR twenty twenty six. And definitely check out RheumNow for all of the best in ACR twenty twenty six content. Hello, everyone.
I'm Richard Conway from Dublin, Ireland, reporting for RheumNow from ACR twenty twenty six. I'm here to talk to you today about an interesting poster from Sunday's poster session. This is abstract number four ninety. Was by Cush et al from France I'm probably pronouncing that name wrong. So my apologies, my French is terrible.
The full title of this is the impact of RA disease activity on pulmonary outcomes in RA, the prospective cohorts translate to? I'm calling it the bad and maybe not so bad as we thought of disease activity in RA ILD. And this is an interesting study because it challenges something which has been a belief of mine, which is that disease activity is a bad thing in OREO in every way, that it makes OREO more likely to happen, that it makes it worse both in terms of progression and in terms of outcomes if that disease activity is ongoing in a patient with RA ILD. So these alters, this is a relatively large study and a relatively long study. So overall in this cohort, this translates to cohort, they have two seventy nine patients, two fifty eight of those were included in this analysis.
They follow-up out to a median of four years. And what they were looking at essentially is disease activity in different ways. But the easiest way to understand this was in comparing moderate high disease activity to the rest of the patients, those in low disease activity and in remission. They measured up by DAS28C or P. And first, in terms of looking at outcomes, having moderate to high disease activity was associated with quite a significant increase in the risk of death or the need for lung transplantation.
So both relatively bad things, I would argue. And this held up in multivariable models with a multivariable hazard ratio of 2.28. So definitely there a reason for us to think that controlling disease activity is good. They looked at ILD progression then, and that's when things got a bit more surprising. So they found progression in fifty percent of patients, which, I mean, that's giving us good power.
It's a good number of patients who are progressing here. And they found no significant association between DAS28 CRP and disease progression. And they looked at us in a variety of ways and still there really didn't seem to be any evidence of that. So to me, that really challenges my own thoughts about disease activity in RAILD and that patients and their progression is not inherently linked to the disease activity. And I'm not really sure how to explain that, and even more so how to explain that and tie that in with the other outcomes, seeing more deaths and lung transplants in those patients.
One thing we should think about is that not all patients progress irrespective of disease activity. So there can be a group of patients who are just kind of static in terms of ILD, but are not progressing, but are quite active in terms of disease activity. I think it's equally true that there's another group of patients who have a very well controlled articular disease, but whose lungs are progressing. And I'm not so sure it's right to say that those patients do not have active disease. My own conceptualization of a lot of those patients is that they do have active rheumatoid disease.
They just don't have it in their joints. That that pulmonary process is still an active inflammatory process, often typified by ground glass infiltrates and inflammatory change on the CT. And I think maybe, again, our conceptualization of rheumatoid arthritis or rheumatoid disease is too joint based at times. And we shouldn't dismiss this ongoing lung disease as a potential indicator of oral activity. And then there's also the issue of those patients with fibrotic disease with a more clinical picture, more similar to IPF, who seem to be almost similar to what we see in IPF that the fibrosis itself could be causing progression of the fibrosis.
So there comes a tipping point with us where it's no longer disease activity, but it's the fibrotic response of the body, which is then generating progression. So I think lots of potential explanations here. I think it does challenge my own thoughts. I'm not so sure I dismiss these patients as being inactive in terms of overall rheumatoid activity, however. So follow me on Twitter at Richard PA Conway for more content from ACR twenty twenty six and check out all the best ACR twenty twenty six content at RoomNow.
Hello, my name is Rinalini Day. I'm a fellow in rheumatology and internal medicine based in London in The UK, and I'm delighted to be reporting for RheumNow here in sunny Orlando for ACR twenty twenty six. Today, I'm delighted to be joined by Doctor. Eric Roberts, is a research scientist at the University of California San Francisco and he is going to be discussing with us a abstract that's going to be presented on Tuesday in the third plenary session which is abstract number 2,807 which is on infliximab biosimilar switching. Thank you very much for joining us today, Eric.
Thanks for having me.
So first of all, this study was conducted in the RISE Registry. So for people who are not familiar with the RISE Registry, could you just give us a bit of a brief overview of that?
Yeah. So RISE is the Rheumatology Informatic System for Effectiveness Registry. It's a qualified clinical data registry owned by the ACR and is designed to help clinicians report their quality measures to CMS. It also doubles as an amazing research resource. The data that's in RISE is what is recorded in the EHR during a clinical encounter and it's publicly available to all researchers.
Great, thank you. So can you just briefly tell us about what you did in this study and actually what happened to disease control after the patients switched?
Yeah, so we were interested in assessing effectiveness in patients who switched and so we got all new users of originator infliximab who were over 18 years old and had between 2015 and 2025. And then we designed a study where we matched switchers to non switchers based on the date of initiation. And then we were able to compare disease activity, from baseline, which was the three months before they switched. And we looked at how disease activity changed in the twelve months after the switch. We modeled effectiveness in a couple of different ways.
We looked at whether or not a patient had a flare, we looked at the odds of having uncontrolled disease activity, and we looked at a continuous pre post change in the numeric value of the score itself. Across all those different operationalizations, across twelve months of follow-up, for patients with both a CDI or a RAPID three, we found very good disease control. No difference between switchers and non switchers.
Okay. Great. Just paring it back a little bit, why was this work necessary in the first place?
Yeah, so biosimilars have been around for a long time. There's many avenues of research within biosimilars. We were really interested in this particular study and thinking about some of the larger trends that are going on. So one, insurance companies have integrated vertically integrated manufacturers and that has spawned co branded biosimilars, which is why we've seen an increase in the number of mandatory formulary changes and with that an increase the number of nonmedical switches. Nonmedical switches are something that clinicians are really worried about and patients are really worried about.
They're worried about how that's affecting long term stable patients disease control. At the same time about a year ago the FDA announced draft guidance relaxing the requirement for a mandatory comparative effectiveness study to have a biosimilar approved. And this was built on scientific evidence. It's a great innovation. It's gonna accelerate drug development timelines and decrease drug development costs.
But we have always taught clinicians to prioritize comparative effectiveness studies to evaluate the safety and efficacy of a drug. So we were really interested in two things. One, concern over non medical switching and how that's affecting patients, also potentially further eroding trust in the system. So we were really interested in using real world evidence data to address this question.
Great. So just going to the real world evidence part of it, you obviously looked at infliximab and its biosimilars. I'm just thinking about my own clinical practice. Is there... Are there other drugs within RICE that you could look at?
I'm thinking particularly about olimumab for example.
Yeah. Yeah. We're interested in all biosimilars, not especially infliximab. We started with infliximab because that is the longest use history in The United States. It's been on the market longest and it's also had the biggest uptake.
Obviously, inflix... Adalimumab biosimilars were introduced in 2023. There wasn't really meaningful uptake in The US until 2024. Okay. So we are planning to replicate this analysis with adalimumab and then as more time progresses, Stelara and tocilizumab.
Okay, great. So yeah, it'd be interesting to see those results when you've got more drugs in the in the analysis. Yes. What could be the applications of this work for real world clinical practice for clinicians and researchers who are watching?
Yeah, think there's an important interplay between trial data and real world evidence data. They're complimentary in a lot of ways. So real world evidence data is it's an independent data source. It's a non selected population. Also, the data is already collected.
So it's really responsible to analyze this and and feed back to providers the data based on their own patients. So what I hope it can do is assure clinicians that these non medical switches are not adversely affecting their patients. Right? We really want to make sure that patients are not scared to make these changes even if they're forced to.
Okay. And just I think actually looking at again the real world evidence side of things, within RISE are you able to see kind of which states or geographically the uptake is like or what the switching is like or did you not really look at that side of things?
We haven't done any geographic sub analyses but Rise does have... It has about 25% of rheumatology practices in The US and there is really good geographic coverage. Okay. So that is something we could do.
Okay, great. Well, thank you for joining me today, Eric. It was great to hear about your work. And if people want to know more, they can join the plenary session on Tuesday of convergence. And that was abstract two eight zero seven.
If you'd like to know more about everything going on here at ACR twenty twenty six, don't forget to follow the coverage on RheumNow. Thank you for watching.
Thanks, Penny. Hello.
I'm Jonathan Kaye from UMass Chan Medical School in Worcester, Massachusetts reporting from ACR Convergence twenty twenty six in Orlando, Florida for RheumNow. I'm here with professor Liam O'Neil from University of Manitoba in Winnipeg, and I hate to put you on the spot, Liam, but you gave a wonderful presentation this morning at the pre RA or RA prevention session about population screening for anti CCP antibodies. You have developed an assay with a dried blood spot, which you can then bring back to the lab, elute the, blood from the filter paper, and then assess it for anti CCP antibodies. Tell us a little bit about this.
Yeah. So we were really motivated by a lot of the work we do in First Nations communities. First Nations in Manitoba, which is where I'm from, they have a very high rates of rheumatoid arthritis, poor outcomes. We do a lot of work in at risk individuals. We wanna understand the pathogenesis of the disease, predicting who's gonna get rheumatoid arthritis.
So much of our work is focused on finding antibody positive individuals who don't have rheumatoid arthritis to study them, hopefully prevent rheumatoid arthritis one day. And so we do a lot of work in remote communities, and we just thought of this idea that it'd be great to not have to do a phlebotomy. We bring lots of research personnel to these communities. We collect tubes. We have to buy a bunch of freezers to store these samples.
So we started working with some of our collaborators in Manitoba, and we've... We we we we developed this assay to, as you said, use a filter paper, which you could store in a freezer. We think they're probably stable at four degrees as well, which is really convenient. And for antibody testing, we think it does a pretty good job, particularly with very high levels, which we know are the highest risk individuals. We think it's very accurate to find people who are antibody positive, and we've deployed it in communities.
We have people who are testing at home, and and they and they really prefer to do it that way. We send people results in the mail if if they're antibody positive or negative to do a bit of knowledge translation, help them understand their risk, and then we bring them back for a follow-up testing.
You bring up a whole bunch of important points. One is population screening, and in conducting studies of prevention approaches to rheumatoid arthritis, identifying anti CCP positive patients or individuals without rheumatoid arthritis is challenging and being able to use this kind of technology at health fairs or elsewhere is very useful. Also, giving patients... Not patients, giving individuals who's consented to population screening the results of a positive test that might suggest they're gonna get a disease that they didn't know they were at risk for is challenging. What kind of responses do you get in terms of following up these patients?
Individuals who test at a health fair, for example, you offer free gift cards. They line up in droves. You do the testing, and then you send them a letter saying, your test came back positive. We'd like you to come into clinic. We're not gonna give you a gift card, but we'd like to draw some blood and, evaluate you further to see if you're gonna get this potentially crippling disease.
What kind of response do you get?
You're right. And it's it's quite heterogeneous, I have to say. Some people are really scared of finding out if they're antibody positive, especially in communities where they see their loved ones really suffering with this disease. We know, again, the outcomes are really often poor in these communities. A lot of it has to do with being remote, and and there are challenges with access to care, but there's also a biological component as well.
And so I think a lot of individuals are quite fearful of this disease. You know, it's up to us to educate people the best we can. And so we think these letters are a really effective way of letting people, helping people understand what what the at risk state really means and hopefully giving them information that they can use. And for everyone who's antibody positive, we always follow-up with a phone call. If we can't get ahold of them, through the letter, we follow-up with a phone call.
We try our best to get a hold of them to bring them back and answer any questions that they might have. The antibody negative people, we send them our information. If they have questions, they can always call us, but it's mostly those antibody positive people. We have to really think about the most ethical and best way to educate them and help them understand what risk really means. Right now, we don't have a lot of good prevention strategies.
So a lot of the education we do has to do with lifestyle modifications that we think are helpful in this at risk state, although we still need more data for that. And then following people. Really the most beneficial thing of being in our study is if you do develop rheumatoid arthritis, we see right away. We get you connected to care immediately. And we know, based on numerous studies, that that's really important for good outcomes.
With such effective therapies that we have for rheumatoid arthritis, people forget what a devastating, potentially crippling disease this is. And getting patients in early, giving those with rheumatoid arthritis access to prompt evaluation and treatment is very important. I can't end this interview without touching upon the First Nation work that Haniel Gavawi has done and that you're now continuing. This is a population of native Canadians who are at very high risk. There's a prevalence of about two percent for rheumatoid arthritis higher than the general population.
And being able to reach out to them with a test in the remote, areas of Manitoba where they live may bring better health care to the native Canadian population.
Yeah. That's absolutely true. And it's it's very complicated to do work with First Nations communities. You know, we adhere to certain principles in Canada that are well established, and it has to be mutually beneficial for the community. You know, the research for them...
For for us, it comes along with clinical care as well. So we have... We're very fortunate to have rheumatologists who do fly in remote care to help connect... Keep us connected to communities. The other thing that we do is we we always show up to communities.
So, you know, I don't just send research staff to go and do the dry blood spot testing. Hany El Gabilawi, who you alluded to, and and I, we show up to these events as well. We do a lot of the screening ourselves so we can talk to people, educate them, and and and speak to leaders in the community to give them updates on our research. So it takes a it takes a it takes a team to actually conduct this type of work, but I think, you know, what Hany has established in Manitoba, and hopefully, I can carry forward, has been a a strong a relationship with communities and a lot of trust building.
That's very important because these are communities where trust has been broken. The Canadian government used to take children away from these communities, bring them to orphanages in Winnipeg and elsewhere, especially in Saskatchewan, where the native Canadian community, the first nation individuals really lost their sense of of trust in the Canadian health care system, and this is wonderful that you're reestablishing it while learning about rheumatoid arthritis pathogenesis treatment and prevention. So, Liam, thank you so much. For more on this and other information from ACR convergence twenty twenty six, tune in to roomnow.com. I'm Jonathan Kaye, Liam O'Neill.
Look forward to seeing you again soon.
Go to rheumnow.live to see the full program and register today. Hi, everyone. Jack Cush, ACR twenty twenty six Orlando, live in the room now booth where there's been a lot of action, a lot of significant teachers and, learners sharing their information with you at this meeting. I've been a bit overwhelmed, but what I... But...
About what I've seen. I want to talk to you about something I saw this morning. The lead presentation at the plenary session, twenty eight zero three is the abstract number. Hannah McClellan from the Duke University School of Medicine, the Molecular Physiology Institute, I think had a fabulous presentation on the impact of lifestyle interventions in older adults with rheumatoid arthritis looking specifically at immune signaling. So we can imagine that's gonna work, right, clinically and give some kind of benefit to people.
But are there immunologic correlates to what happens with lifestyle intervention? What we're talking about here is, especially as RA patients get older, sarcopenia is a problem at least twenty five percent. Patients get weaker, and getting weaker, they do less, they do less, they hurt more, they hurt more, they do less. It's a spiral down. Right?
I always try to get my older patients with RA to make their number one goal getting strong. If you get strong, things get better. And that's what they did in this trial. The trial was called sweat and chat. And what they did was...
It's a sixteen week trial of older RA patients. They're seropositive, and they are randomized to either sixteen weeks of two visits about diet, exercise, counseling, and then, and that's the chat cohort, the control cohort. The active intervention cohort is the sweat cohort, s w e t by the way, where they get regular ongoing aerobic resistance exercise training where they're aiming at a hundred and fifty minutes a week and that along with dietary interventions and then doing a readout on that at the end of the study period. The results were pretty dramatic. So they did get better with the intervention and the clinical improvement was shown significant clinical improvement in dash 28 CRP, in swollen joint count, and patient global assessments were all significant.
Sed rate and CRP, not significant. Interestingly, cytokines across the board, no change. But cellular subset analysis done by facts showed significant decreases in Treg cells, in CD four PD one cells, in CD four memory cells, and NK cells across the board for the people that had the active intervention, lifestyle intervention of diet and vigorous exercise. As I said, the plethora of metabolic and cytokine readouts showed no significance. And then they went on to show a lot of correlation with these biologic findings with clinical effects and you have to look at the abstract to really see what that all that meant.
In the end, they showed that very clearly that the lifestyle intervention led to, a modulation of lymphocyte profiling. Okay? And basically changed patients from... As far as their strength, their tone, their RA activity, changed them from, you know, sort of a failing older patient to someone whose biology was that of a younger patient. And the net result is that, you know, lymphocytes, disease activity, and muscle properties were greatly enhanced by the lifestyle intervention.
This was a pilot trial. Right? So there's only twenty people that that had the intervention. But I think it's strong data about what we should be doing and certainly a call for more information about lifestyle interventions and what the benefits are gonna be in rheumatoid arthritis. Tune in for more RheumNow.
Hello. I'm Jonathan Kaye from UMass Chan Medical School in Worcester, Massachusetts reporting for RheumNow at ACR Convergence twenty twenty six in Orlando, Florida. Today, I have Peter Mandel and Gregor Mitter from the University of Vienna, School of Medicine who've been presenting a very interesting poster about the use of fibroblast activation protein inhibitor coupled to lutetium, a radio labeled nucleotide or a nuclide to target the fibroblasts in rheumatoid arthritis synovium and treat active rheumatoid arthritis that's been resistant to other conventional therapies. So Peter, Gregor, tell us a little bit about what you found.
Yeah. So we had two patients, one with RA and one with PSA, who were difficult to treat with a long standing story of multiple drug failure. We tried to make this approach, which has been known to oncology, to inject intravenously fibroblast activation protein inhibitor coupled with lutetium. We saw quite good results in decrease of C. Diffeile, swollen joint count, tender joint count in both patients.
So this is very interesting. And Peter, you're targeting tissue resident fibroblasts. It's very difficult to target fibroblasts because unlike circulating t cells or b cells, these are in the synovium. How did you come up with this novel idea to take this approach?
So as Greg already mentioned, this approach is already used. This compound is already used in oncology where the idea is of course to target, bring the, the lutetium is a beta emitter, so it's a systemic radio ligand therapy. In our case, there the idea is that it would, because each tumor has a fibroblast environment or structure around it, that it would bring thereby the emitter within the vicinity of the tumor cells. In our case, this would be in a way analogous to radio synovial orthesis where we would inject it into a single joint, but in our case, we give this systemically. And we do see, we saw very, you know, in our diagnostic studies, we do see high uptake of of the the gallium label so that the diagnostic FAPI, in the synovial joints of patients, the two patients, Gregor mentioned, with with difficult to treat one with RA and the other one with PSA.
So this is a targeted approach, going back to the, probably twenty, thirty years ago using yttrium, injected into the joint in a nonspecific way of ablating the inflamed synovium. But here, you're using a targeted agent to target those fibroblasts that are probably pathogenic in the synovium.
Yes. It it... As analogy, this is not napalm bombing a forest, but a... If if if you may, a targeted intervention of a certain species of plants.
So this is fantastic. Where do you see this going? You've treated two patients. One with so called difficult to treat rheumatoid arthritis, another with multidrug experience psoriatic arthritis. What are your current plans for further development?
So obviously we want to take this forward and treat more patients. So what we've seen importantly is we saw both in a decrease in the standardized uptake values on the follow-up PET if we did that. We also did sino biopsies of these patients before and after the treatment and saw a reduction in the number of fat positive expressing fibroblasts. And we did see, particularly in the RA patient, a steady reduction of disease activity.
So this is wonderful. So this is now a new era of targeted therapies, but using radionuclide instead of antibodies or other protein derived drugs to treat difficult to treat rheumatoid arthritis and other forms of inflammatory arthritis. For more information about this and other topics, please go to roomnow.com. I'm Jonathan Kaye with Peter Mandel and Gregor Mitter, here at ACR Convergence twenty twenty six. See you again soon.
Thanks.
David
Lu here for RheumNow's coverage of ACI Convergence twenty twenty six, and I'm gonna hit some RA things today. Really interesting posters out there on the poster floor, answering the questions that we're... We come across in everyday practice. One of those that gets raised a bit and I think it started a long time ago when we didn't have certainty about things is about whether in a patient with RA who's had cancer, which does happen, is it okay to restart the biologic in the couple of years after, at any point after? What do we do about that?
And original guidance, if you go back, say fifteen years ago, was very conservative on this, that we should do it very cautiously, whether some people were withholding biologics for five years after. And it's very hard to get the data for these things as well for a number of reasons. Firstly, the outcome fundamentally is about new cancers coming back, new cancer coming back. And that takes time. There are a lot of factors that go into that that confound the situation.
It's hard to study these things ethically as well and so what inevitably happens is that we're reliant on observational data. You go back, I think two years ago now, just under two years... Well, just under two years ago, we saw some really excellent, data from Maria Suarez Almazar's group, at MD Anderson, looking at the situations where we gave biologics in that period of time, a couple of years after cancer diagnosis in lung cancer, some big cancers, colorectal cancer. We saw that actually the outcomes seemed pretty favorable. They were relatively small numbers.
It's a pretty big cancer centre, but it's still only one single centre. At this meeting, abstract two four zero nine was a big Spanish collaborative, with names you might have heard of, talking about this, they have a registry called the ARCA registry, the ARCA registry, where they've tried to put together a lot of these data, for different biologics. I should say that the MD Anderson, data was only TNF inhibitors and I guess there's questions about other, biologic, agents including abatacept and what that might mean for cancer recurrence versus something like methotrexate or a CSD mod which I guess we're more comfortable with possibly just from the basis of more experience. Seven twenty eight patients with rheumatoid arthritis, all of whom had previous cancer followed over the course of time. We don't have all the data on exactly when things were initiated and that's a fundamental limitation.
But what I will tell you is that they did not find any differences, significant differences between the biologics and the CS DMARDs. But if anything, things trended that, in fact, the biology DMARD patients did better in terms of cancer free survival, in terms of new instant cancers. So what does that mean? Well, I will tell you that naturally there's gonna be some channeling bias in that period of time over the course of decades. And, knowing that maybe those higher risk for recurrence or new cancer patients are going to have had some CSD MADs preferentially over having recommenced or started in biologics.
But all the signals do seem to suggest that if anything, there doesn't... There's not the same, point of concern there, and you have to ask yourself the concern that we've had with this is that at best overcautious and actually probably not based on things knowing that it's a very real cost in not giving rheumatoid arthritis patients the effective therapies they deserve and knowing as well that in a number of different other situations including with people receiving biologics for immune related adverse events for checkpoint inhibitors that we do use them in these situations and the world doesn't entirely fall in that situation either. So hopefully a bit of reassurance with that. Everything great on rheumatoid arthritis, you know where to go, roomnow.com.
Hello, everyone. I'm Richard Conway from Dublin, Ireland. I'm reporting from ACR twenty twenty six for RheumNow. I'm here to talk to you today about an abstract that was presented at Monday's abstract session. And this is an ILD abstract, but I think maybe some ILD people will not have encountered it as was presented in the epidemiology and public health abstract session and not the rheumatoid abstract session.
This is by Kim et al from Korea. And the proper title of this is Lung Cancer Risk in RA and RA A Competing Risk Analysis. I've called it RA ILD in lung cancer. I think that's, it does what it says on the team. That's what it's about.
This is a single center cohort, relatively large numbers of patients, however, six sixty four rheumatoid arthritis patients, two thirty of those had ILD, which is a lot. That is more than a third of their patients. So it seems ILD is quite common in Korea. So that was one of the things they were looking at. And the other thing was lung cancer.
Lung cancer, thankfully, slightly less common seen in thirteen patients in this cohort. Ten of those had ILD and three patients who didn't have ILD. When just looking at the basic demographics here, kind of as you'd expect, patients with ILD were more likely to be older. They're more likely to be men. They're more likely to be smokers.
So all kind of known risk factors for ILD and all also known risk factors for lung cancer. So one question with studies of this nature is always, is this just shared risk factors giving us these two conditions? But the authors, in fairness, have tried to control for that in, I would say, relatively complicated statistical methodology. So those rolling numbers, they give us an incident rate of lung cancer in patients with RA ILD of one point one three per one hundred patient years and in those without ILD, but who still have RA of zero point one two per one hundred patient years. They then looked at this in two main ways.
The first was inverse probability of treatment rating propensity score analysis methodology. That gave us an adjusted incident ratio of seven point one for lung cancer in patients who had RA LD compared to those with just RA. So that was quite high. There are relatively large confidence intervals on this being generated by relatively small numbers of patients who had lung cancer. So it went from one point four eight to thirty four point zero seven.
So it's hard to get an exact estimate, but certainly significantly more common in patients with ILD. They then went on and did another analysis, competing risk analysis, and that kind of confirmed the same findings. The hazard ratio here was 8.13. Again, confidence intervals are low, slightly less so going from 2.43 to 27.16. So that is giving us a relatively clear evidence here that these patients are more likely to get lung cancer and that we should be on lookout for it.
I guess there is always the possibility of bias around testing here. Patients with ILD will generally be under relatively closer follow-up. They'll be seen quite possibly by a respiratory physician as well as a rheumatologist. They may be getting serial CT scans, which of course will identify lung cancer at an earlier stage. So there's the possibility here that we're picking up more lung cancers either because we're seeing them earlier and they haven't yet been diagnosed in the RA population, or that we are seeing them because we're doing more testing and we're picking up lung cancers that would never have been a clinically significant problem.
I don't have a good feel for how true that is in lung cancer. It's obviously that happens a lot in things like prostate cancer, probably slightly less of a realistic explanation for lung cancer, which tends to be quite aggressive. So overall, I think this tells us we need to think about lung cancer in these patients. I'm not sure it would hugely change my clinical practice. I think obviously these patients were already on the lookout for their pulmonary outcomes and any change in their pulmonary status.
So I'm not sure it will hugely change what I do. Perhaps in that kind of relatively stable ILD population who may not be getting serial scans, I might start to think that maybe we should be doing them more frequently and delight my radiologist when I suggest they need to do more scans on these people as screening tests. So check out my Twitter at rechickpaconway for more of my content from ACR twenty twenty six. And definitely check out RheumNow for all of the best in ACR twenty twenty six content. Hello, everyone.
I'm Richard Conway from Dublin, Ireland, reporting for RheumNow from ACR twenty twenty six. I'm here to talk to you today about an interesting poster from Sunday's poster session. This is abstract number four ninety. Was by Cush et al from France I'm probably pronouncing that name wrong. So my apologies, my French is terrible.
The full title of this is the impact of RA disease activity on pulmonary outcomes in RA, the prospective cohorts translate to? I'm calling it the bad and maybe not so bad as we thought of disease activity in RA ILD. And this is an interesting study because it challenges something which has been a belief of mine, which is that disease activity is a bad thing in OREO in every way, that it makes OREO more likely to happen, that it makes it worse both in terms of progression and in terms of outcomes if that disease activity is ongoing in a patient with RA ILD. So these alters, this is a relatively large study and a relatively long study. So overall in this cohort, this translates to cohort, they have two seventy nine patients, two fifty eight of those were included in this analysis.
They follow-up out to a median of four years. And what they were looking at essentially is disease activity in different ways. But the easiest way to understand this was in comparing moderate high disease activity to the rest of the patients, those in low disease activity and in remission. They measured up by DAS28C or P. And first, in terms of looking at outcomes, having moderate to high disease activity was associated with quite a significant increase in the risk of death or the need for lung transplantation.
So both relatively bad things, I would argue. And this held up in multivariable models with a multivariable hazard ratio of 2.28. So definitely there a reason for us to think that controlling disease activity is good. They looked at ILD progression then, and that's when things got a bit more surprising. So they found progression in fifty percent of patients, which, I mean, that's giving us good power.
It's a good number of patients who are progressing here. And they found no significant association between DAS28 CRP and disease progression. And they looked at us in a variety of ways and still there really didn't seem to be any evidence of that. So to me, that really challenges my own thoughts about disease activity in RAILD and that patients and their progression is not inherently linked to the disease activity. And I'm not really sure how to explain that, and even more so how to explain that and tie that in with the other outcomes, seeing more deaths and lung transplants in those patients.
One thing we should think about is that not all patients progress irrespective of disease activity. So there can be a group of patients who are just kind of static in terms of ILD, but are not progressing, but are quite active in terms of disease activity. I think it's equally true that there's another group of patients who have a very well controlled articular disease, but whose lungs are progressing. And I'm not so sure it's right to say that those patients do not have active disease. My own conceptualization of a lot of those patients is that they do have active rheumatoid disease.
They just don't have it in their joints. That that pulmonary process is still an active inflammatory process, often typified by ground glass infiltrates and inflammatory change on the CT. And I think maybe, again, our conceptualization of rheumatoid arthritis or rheumatoid disease is too joint based at times. And we shouldn't dismiss this ongoing lung disease as a potential indicator of oral activity. And then there's also the issue of those patients with fibrotic disease with a more clinical picture, more similar to IPF, who seem to be almost similar to what we see in IPF that the fibrosis itself could be causing progression of the fibrosis.
So there comes a tipping point with us where it's no longer disease activity, but it's the fibrotic response of the body, which is then generating progression. So I think lots of potential explanations here. I think it does challenge my own thoughts. I'm not so sure I dismiss these patients as being inactive in terms of overall rheumatoid activity, however. So follow me on Twitter at Richard PA Conway for more content from ACR twenty twenty six and check out all the best ACR twenty twenty six content at RoomNow.
Hello, my name is Rinalini Day. I'm a fellow in rheumatology and internal medicine based in London in The UK, and I'm delighted to be reporting for RheumNow here in sunny Orlando for ACR twenty twenty six. Today, I'm delighted to be joined by Doctor. Eric Roberts, is a research scientist at the University of California San Francisco and he is going to be discussing with us a abstract that's going to be presented on Tuesday in the third plenary session which is abstract number 2,807 which is on infliximab biosimilar switching. Thank you very much for joining us today, Eric.
Thanks for having me.
So first of all, this study was conducted in the RISE Registry. So for people who are not familiar with the RISE Registry, could you just give us a bit of a brief overview of that?
Yeah. So RISE is the Rheumatology Informatic System for Effectiveness Registry. It's a qualified clinical data registry owned by the ACR and is designed to help clinicians report their quality measures to CMS. It also doubles as an amazing research resource. The data that's in RISE is what is recorded in the EHR during a clinical encounter and it's publicly available to all researchers.
Great, thank you. So can you just briefly tell us about what you did in this study and actually what happened to disease control after the patients switched?
Yeah, so we were interested in assessing effectiveness in patients who switched and so we got all new users of originator infliximab who were over 18 years old and had between 2015 and 2025. And then we designed a study where we matched switchers to non switchers based on the date of initiation. And then we were able to compare disease activity, from baseline, which was the three months before they switched. And we looked at how disease activity changed in the twelve months after the switch. We modeled effectiveness in a couple of different ways.
We looked at whether or not a patient had a flare, we looked at the odds of having uncontrolled disease activity, and we looked at a continuous pre post change in the numeric value of the score itself. Across all those different operationalizations, across twelve months of follow-up, for patients with both a CDI or a RAPID three, we found very good disease control. No difference between switchers and non switchers.
Okay. Great. Just paring it back a little bit, why was this work necessary in the first place?
Yeah, so biosimilars have been around for a long time. There's many avenues of research within biosimilars. We were really interested in this particular study and thinking about some of the larger trends that are going on. So one, insurance companies have integrated vertically integrated manufacturers and that has spawned co branded biosimilars, which is why we've seen an increase in the number of mandatory formulary changes and with that an increase the number of nonmedical switches. Nonmedical switches are something that clinicians are really worried about and patients are really worried about.
They're worried about how that's affecting long term stable patients disease control. At the same time about a year ago the FDA announced draft guidance relaxing the requirement for a mandatory comparative effectiveness study to have a biosimilar approved. And this was built on scientific evidence. It's a great innovation. It's gonna accelerate drug development timelines and decrease drug development costs.
But we have always taught clinicians to prioritize comparative effectiveness studies to evaluate the safety and efficacy of a drug. So we were really interested in two things. One, concern over non medical switching and how that's affecting patients, also potentially further eroding trust in the system. So we were really interested in using real world evidence data to address this question.
Great. So just going to the real world evidence part of it, you obviously looked at infliximab and its biosimilars. I'm just thinking about my own clinical practice. Is there... Are there other drugs within RICE that you could look at?
I'm thinking particularly about olimumab for example.
Yeah. Yeah. We're interested in all biosimilars, not especially infliximab. We started with infliximab because that is the longest use history in The United States. It's been on the market longest and it's also had the biggest uptake.
Obviously, inflix... Adalimumab biosimilars were introduced in 2023. There wasn't really meaningful uptake in The US until 2024. Okay. So we are planning to replicate this analysis with adalimumab and then as more time progresses, Stelara and tocilizumab.
Okay, great. So yeah, it'd be interesting to see those results when you've got more drugs in the in the analysis. Yes. What could be the applications of this work for real world clinical practice for clinicians and researchers who are watching?
Yeah, think there's an important interplay between trial data and real world evidence data. They're complimentary in a lot of ways. So real world evidence data is it's an independent data source. It's a non selected population. Also, the data is already collected.
So it's really responsible to analyze this and and feed back to providers the data based on their own patients. So what I hope it can do is assure clinicians that these non medical switches are not adversely affecting their patients. Right? We really want to make sure that patients are not scared to make these changes even if they're forced to.
Okay. And just I think actually looking at again the real world evidence side of things, within RISE are you able to see kind of which states or geographically the uptake is like or what the switching is like or did you not really look at that side of things?
We haven't done any geographic sub analyses but Rise does have... It has about 25% of rheumatology practices in The US and there is really good geographic coverage. Okay. So that is something we could do.
Okay, great. Well, thank you for joining me today, Eric. It was great to hear about your work. And if people want to know more, they can join the plenary session on Tuesday of convergence. And that was abstract two eight zero seven.
If you'd like to know more about everything going on here at ACR twenty twenty six, don't forget to follow the coverage on RheumNow. Thank you for watching.
Thanks, Penny. Hello.
I'm Jonathan Kaye from UMass Chan Medical School in Worcester, Massachusetts reporting from ACR Convergence twenty twenty six in Orlando, Florida for RheumNow. I'm here with professor Liam O'Neil from University of Manitoba in Winnipeg, and I hate to put you on the spot, Liam, but you gave a wonderful presentation this morning at the pre RA or RA prevention session about population screening for anti CCP antibodies. You have developed an assay with a dried blood spot, which you can then bring back to the lab, elute the, blood from the filter paper, and then assess it for anti CCP antibodies. Tell us a little bit about this.
Yeah. So we were really motivated by a lot of the work we do in First Nations communities. First Nations in Manitoba, which is where I'm from, they have a very high rates of rheumatoid arthritis, poor outcomes. We do a lot of work in at risk individuals. We wanna understand the pathogenesis of the disease, predicting who's gonna get rheumatoid arthritis.
So much of our work is focused on finding antibody positive individuals who don't have rheumatoid arthritis to study them, hopefully prevent rheumatoid arthritis one day. And so we do a lot of work in remote communities, and we just thought of this idea that it'd be great to not have to do a phlebotomy. We bring lots of research personnel to these communities. We collect tubes. We have to buy a bunch of freezers to store these samples.
So we started working with some of our collaborators in Manitoba, and we've... We we we we developed this assay to, as you said, use a filter paper, which you could store in a freezer. We think they're probably stable at four degrees as well, which is really convenient. And for antibody testing, we think it does a pretty good job, particularly with very high levels, which we know are the highest risk individuals. We think it's very accurate to find people who are antibody positive, and we've deployed it in communities.
We have people who are testing at home, and and they and they really prefer to do it that way. We send people results in the mail if if they're antibody positive or negative to do a bit of knowledge translation, help them understand their risk, and then we bring them back for a follow-up testing.
You bring up a whole bunch of important points. One is population screening, and in conducting studies of prevention approaches to rheumatoid arthritis, identifying anti CCP positive patients or individuals without rheumatoid arthritis is challenging and being able to use this kind of technology at health fairs or elsewhere is very useful. Also, giving patients... Not patients, giving individuals who's consented to population screening the results of a positive test that might suggest they're gonna get a disease that they didn't know they were at risk for is challenging. What kind of responses do you get in terms of following up these patients?
Individuals who test at a health fair, for example, you offer free gift cards. They line up in droves. You do the testing, and then you send them a letter saying, your test came back positive. We'd like you to come into clinic. We're not gonna give you a gift card, but we'd like to draw some blood and, evaluate you further to see if you're gonna get this potentially crippling disease.
What kind of response do you get?
You're right. And it's it's quite heterogeneous, I have to say. Some people are really scared of finding out if they're antibody positive, especially in communities where they see their loved ones really suffering with this disease. We know, again, the outcomes are really often poor in these communities. A lot of it has to do with being remote, and and there are challenges with access to care, but there's also a biological component as well.
And so I think a lot of individuals are quite fearful of this disease. You know, it's up to us to educate people the best we can. And so we think these letters are a really effective way of letting people, helping people understand what what the at risk state really means and hopefully giving them information that they can use. And for everyone who's antibody positive, we always follow-up with a phone call. If we can't get ahold of them, through the letter, we follow-up with a phone call.
We try our best to get a hold of them to bring them back and answer any questions that they might have. The antibody negative people, we send them our information. If they have questions, they can always call us, but it's mostly those antibody positive people. We have to really think about the most ethical and best way to educate them and help them understand what risk really means. Right now, we don't have a lot of good prevention strategies.
So a lot of the education we do has to do with lifestyle modifications that we think are helpful in this at risk state, although we still need more data for that. And then following people. Really the most beneficial thing of being in our study is if you do develop rheumatoid arthritis, we see right away. We get you connected to care immediately. And we know, based on numerous studies, that that's really important for good outcomes.
With such effective therapies that we have for rheumatoid arthritis, people forget what a devastating, potentially crippling disease this is. And getting patients in early, giving those with rheumatoid arthritis access to prompt evaluation and treatment is very important. I can't end this interview without touching upon the First Nation work that Haniel Gavawi has done and that you're now continuing. This is a population of native Canadians who are at very high risk. There's a prevalence of about two percent for rheumatoid arthritis higher than the general population.
And being able to reach out to them with a test in the remote, areas of Manitoba where they live may bring better health care to the native Canadian population.
Yeah. That's absolutely true. And it's it's very complicated to do work with First Nations communities. You know, we adhere to certain principles in Canada that are well established, and it has to be mutually beneficial for the community. You know, the research for them...
For for us, it comes along with clinical care as well. So we have... We're very fortunate to have rheumatologists who do fly in remote care to help connect... Keep us connected to communities. The other thing that we do is we we always show up to communities.
So, you know, I don't just send research staff to go and do the dry blood spot testing. Hany El Gabilawi, who you alluded to, and and I, we show up to these events as well. We do a lot of the screening ourselves so we can talk to people, educate them, and and and speak to leaders in the community to give them updates on our research. So it takes a it takes a it takes a team to actually conduct this type of work, but I think, you know, what Hany has established in Manitoba, and hopefully, I can carry forward, has been a a strong a relationship with communities and a lot of trust building.
That's very important because these are communities where trust has been broken. The Canadian government used to take children away from these communities, bring them to orphanages in Winnipeg and elsewhere, especially in Saskatchewan, where the native Canadian community, the first nation individuals really lost their sense of of trust in the Canadian health care system, and this is wonderful that you're reestablishing it while learning about rheumatoid arthritis pathogenesis treatment and prevention. So, Liam, thank you so much. For more on this and other information from ACR convergence twenty twenty six, tune in to roomnow.com. I'm Jonathan Kaye, Liam O'Neill.
Look forward to seeing you again soon.

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.